Have a feature idea you'd love to see implemented? Let us know!

MCRB Seres Therapeutics Inc

Price (delayed)

$0.7778

Market cap

$118.02M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.18

Enterprise value

$249.54M

Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to ...

Highlights
The EPS has shrunk by 97% QoQ but it has increased by 4.8% YoY
Seres Therapeutics's gross profit has shrunk by 100% YoY and by 100% QoQ
MCRB's revenue has dropped by 100% year-on-year and by 100% since the previous quarter

Key stats

What are the main financial stats of MCRB
Market
Shares outstanding
151.73M
Market cap
$118.02M
Enterprise value
$249.54M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
315.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
667.21
Earnings
Revenue
$374,000
EBIT
-$145.95M
EBITDA
-$130.26M
Free cash flow
-$184.64M
Per share
EPS
-$1.18
Free cash flow per share
-$1.22
Book value per share
-$0.57
Revenue per share
$0
TBVPS
$2.12
Balance sheet
Total assets
$321.73M
Total liabilities
$408.81M
Debt
$212.63M
Equity
-$87.07M
Working capital
$40.98M
Liquidity
Debt to equity
-2.44
Current ratio
1.38
Quick ratio
0.92
Net debt/EBITDA
-1.01
Margins
EBITDA margin
-34,827.5%
Gross margin
100%
Net margin
-43,343.6%
Operating margin
-42,211.2%
Efficiency
Return on assets
-46.7%
Return on equity
N/A
Return on invested capital
-43.5%
Return on capital employed
-68.4%
Return on sales
-39,025.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MCRB stock price

How has the Seres Therapeutics stock price performed over time
Intraday
0.87%
1 week
2.75%
1 month
-17.79%
1 year
-46.36%
YTD
-44.44%
QTD
-17.79%

Financial performance

How have Seres Therapeutics's revenue and profit performed over time
Revenue
$374,000
Gross profit
$374,000
Operating income
-$157.87M
Net income
-$162.11M
Gross margin
100%
Net margin
-43,343.6%
MCRB's operating income has dropped by 105% since the previous quarter and by 6% year-on-year
Seres Therapeutics's gross profit has shrunk by 100% YoY and by 100% QoQ
MCRB's revenue has dropped by 100% year-on-year and by 100% since the previous quarter
Seres Therapeutics's net income has plunged by 96% from the previous quarter and by 6% YoY

Growth

What is Seres Therapeutics's growth rate over time

Valuation

What is Seres Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
315.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
667.21
The EPS has shrunk by 97% QoQ but it has increased by 4.8% YoY
The equity has decreased by 46% QoQ
MCRB's revenue has dropped by 100% year-on-year and by 100% since the previous quarter

Efficiency

How efficient is Seres Therapeutics business performance
The return on invested capital has dropped by 112% since the previous quarter but it has grown by 31% year-on-year
The company's return on assets has shrunk by 108% QoQ

Dividends

What is MCRB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MCRB.

Financial health

How did Seres Therapeutics financials performed over time
The total assets is 21% lower than the total liabilities
The quick ratio has shrunk by 71% YoY and by 29% QoQ
MCRB's current ratio has shrunk by 57% YoY and by 18% QoQ
Seres Therapeutics's debt to equity has shrunk by 126% YoY but it has increased by 32% QoQ
The equity has decreased by 46% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.